SK143597A3 - Clostridial toxin derivatives able to modify peripheral sensory afferent functions - Google Patents
Clostridial toxin derivatives able to modify peripheral sensory afferent functions Download PDFInfo
- Publication number
- SK143597A3 SK143597A3 SK1435-97A SK143597A SK143597A3 SK 143597 A3 SK143597 A3 SK 143597A3 SK 143597 A SK143597 A SK 143597A SK 143597 A3 SK143597 A3 SK 143597A3
- Authority
- SK
- Slovakia
- Prior art keywords
- composition
- chain
- composition according
- clostridial neurotoxin
- fragment
- Prior art date
Links
- 230000001953 sensory effect Effects 0.000 title claims description 39
- 230000002093 peripheral effect Effects 0.000 title claims description 10
- 230000006870 function Effects 0.000 title claims description 8
- 231100001102 clostridial toxin Toxicity 0.000 title description 4
- 230000000694 effects Effects 0.000 claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims abstract description 31
- 230000027455 binding Effects 0.000 claims abstract description 17
- 210000000172 cytosol Anatomy 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 102
- 208000002193 Pain Diseases 0.000 claims description 61
- 210000003766 afferent neuron Anatomy 0.000 claims description 50
- 230000036407 pain Effects 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 47
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 45
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 32
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 32
- 229940053128 nerve growth factor Drugs 0.000 claims description 32
- 239000002858 neurotransmitter agent Substances 0.000 claims description 32
- 210000002569 neuron Anatomy 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- 239000002581 neurotoxin Substances 0.000 claims description 25
- 231100000618 neurotoxin Toxicity 0.000 claims description 25
- 230000003040 nociceptive effect Effects 0.000 claims description 25
- 108030001720 Bontoxilysin Proteins 0.000 claims description 21
- 241001112695 Clostridiales Species 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 101710138657 Neurotoxin Proteins 0.000 claims description 10
- 210000001176 projection neuron Anatomy 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 230000005540 biological transmission Effects 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 210000002161 motor neuron Anatomy 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 229940053031 botulinum toxin Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000000946 synaptic effect Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 4
- 230000008058 pain sensation Effects 0.000 claims description 4
- 210000000063 presynaptic terminal Anatomy 0.000 claims description 4
- 230000017854 proteolysis Effects 0.000 claims description 4
- 230000007441 retrograde transport Effects 0.000 claims description 4
- 230000000720 neurosecretory effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091008039 hormone receptors Proteins 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 229940094657 botulinum toxin type a Drugs 0.000 claims 4
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 102000028517 Neuropeptide receptor Human genes 0.000 claims 1
- 108070000018 Neuropeptide receptor Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 17
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000012528 membrane Substances 0.000 abstract description 5
- 230000012202 endocytosis Effects 0.000 abstract description 4
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 230000005945 translocation Effects 0.000 abstract description 2
- 210000001163 endosome Anatomy 0.000 abstract 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 208000000094 Chronic Pain Diseases 0.000 description 9
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 9
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940005483 opioid analgesics Drugs 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- 210000005056 cell body Anatomy 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 6
- 108010059378 Endopeptidases Proteins 0.000 description 5
- 102000005593 Endopeptidases Human genes 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 108090000189 Neuropeptides Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000000609 ganglia Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 3
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 102400001355 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 229920004929 Triton X-114 Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001679 solitary nucleus Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QXXBUXBKXUHVQH-FMTGAZOMSA-N (2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-3-hydroxy-2-[[2-[[2-[[(2s)-1-[(2s)-1-[(2s)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-3-methylbutan Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)C(C)C)CCN1C(=O)[C@@H]1CCC(=O)N1 QXXBUXBKXUHVQH-FMTGAZOMSA-N 0.000 description 1
- MISJXUDJCSZFAH-UHFFFAOYSA-N 1-sulfanylpyridin-2-one Chemical compound SN1C=CC=CC1=O MISJXUDJCSZFAH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000003626 afferent pathway Anatomy 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010001247 head activator peptide Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- -1 lactose saccharide Chemical class 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003466 luteinizing hormone derivative Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001386 multineuronal effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000029854 negative regulation of acetylcholine secretion Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009155 sensory pathway Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 210000004001 thalamic nuclei Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000000836 trigeminal nuclei Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9508204.6A GB9508204D0 (en) | 1995-04-21 | 1995-04-21 | A novel agent able to modify peripheral afferent function |
| PCT/GB1996/000916 WO1996033273A1 (en) | 1995-04-21 | 1996-04-16 | Botulinum toxin derivatives able to modify peripheral sensory afferent functions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK143597A3 true SK143597A3 (en) | 1998-09-09 |
Family
ID=10773357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1435-97A SK143597A3 (en) | 1995-04-21 | 1996-04-16 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US5989545A (xx) |
| EP (1) | EP0826051B1 (xx) |
| JP (1) | JP4304241B2 (xx) |
| KR (1) | KR19990007943A (xx) |
| CN (1) | CN1122718C (xx) |
| AT (1) | ATE274581T1 (xx) |
| AU (1) | AU705924B2 (xx) |
| BG (1) | BG101984A (xx) |
| BR (1) | BR9609870A (xx) |
| CA (1) | CA2218857C (xx) |
| CZ (1) | CZ332297A3 (xx) |
| DE (1) | DE69633228T2 (xx) |
| ES (1) | ES2225876T3 (xx) |
| GB (1) | GB9508204D0 (xx) |
| HU (1) | HUP9802392A3 (xx) |
| NO (1) | NO974845L (xx) |
| NZ (1) | NZ305411A (xx) |
| PL (1) | PL323006A1 (xx) |
| PT (1) | PT826051E (xx) |
| RU (1) | RU2165976C2 (xx) |
| SG (1) | SG52602A1 (xx) |
| SK (1) | SK143597A3 (xx) |
| TR (1) | TR199701215T1 (xx) |
| WO (1) | WO1996033273A1 (xx) |
| ZA (1) | ZA963129B (xx) |
Families Citing this family (248)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| CN1321683C (zh) * | 1997-07-15 | 2007-06-20 | 科罗拉多大学董事会 | 神经毒素疗法在泌尿系及相关疾病治疗中的应用 |
| US7470431B2 (en) * | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
| US9066943B2 (en) * | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
| US7455845B2 (en) * | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
| US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US6600626B2 (en) | 1998-07-17 | 2003-07-29 | Hitachi, Ltd. | Magnetic disk apparatus |
| US6376460B2 (en) * | 1998-08-07 | 2002-04-23 | Flinders Technologies Pty. Ltd. | Method of modulating cellular activity |
| US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| GB9824282D0 (en) * | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| JP2000169389A (ja) * | 1998-12-08 | 2000-06-20 | Sumitomo Pharmaceut Co Ltd | 触覚異常治療剤 |
| US6652864B1 (en) * | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| GB9907429D0 (en) * | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| ES2277854T5 (es) | 1999-08-25 | 2011-02-04 | Allergan, Inc. | Neurotoxinas recombinantes activables. |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) * | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| PT1234043E (pt) * | 1999-12-02 | 2004-07-30 | Health Prot Agency | Construcoes para a entrega de agentes terapeuticos a celulas neuronais |
| US7368532B2 (en) * | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6821520B2 (en) * | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6565870B1 (en) * | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| US20030195707A1 (en) * | 2000-05-25 | 2003-10-16 | Schork Nicholas J | Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof |
| US20020077775A1 (en) * | 2000-05-25 | 2002-06-20 | Schork Nicholas J. | Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof |
| US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| US20050214327A1 (en) * | 2000-06-02 | 2005-09-29 | Allergan, Inc. | Neurotoxin-containing suppositories and related methods |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| CA2413301A1 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| US7691983B2 (en) | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
| US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
| US20040219619A1 (en) * | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
| AU8466501A (en) * | 2000-07-21 | 2002-02-05 | Essentia Biosystems Inc | Multi-component biological transport systems |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7223577B2 (en) | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
| US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| US20070048335A1 (en) * | 2000-12-29 | 2007-03-01 | Allergan, Inc. | Methods for treating pain and hyperhidrosis |
| CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
| CA2456571A1 (en) * | 2001-08-10 | 2003-02-20 | Genset Sa | Human secreted proteins, their encoding polynucleotides, and uses thereof |
| US7208285B2 (en) * | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
| US7332567B2 (en) * | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US7374896B2 (en) * | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| US8022172B2 (en) * | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
| US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| CA2369810C (en) | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
| US20050106183A1 (en) * | 2002-01-31 | 2005-05-19 | Lamb Gregory B. | Method of treating pain |
| US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
| US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7183066B2 (en) * | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| CA2501856A1 (en) * | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
| US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| US20040115727A1 (en) * | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
| JP2006519761A (ja) * | 2002-12-20 | 2006-08-31 | ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド | 改善された薬学的ボツリヌス毒素組成物 |
| EP1599213A4 (en) * | 2003-02-24 | 2009-07-15 | Ira Sanders | CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| ES2381091T3 (es) * | 2003-03-06 | 2012-05-23 | Botulinum Toxin Research Associates, Inc. | Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica |
| US7393538B2 (en) * | 2003-04-25 | 2008-07-01 | Ackerman Alan H | Clostridial toxin treatment for dermatillomania |
| US7393537B2 (en) * | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
| US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
| US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
| US7390496B2 (en) * | 2003-04-25 | 2008-06-24 | Allergan, Inc. | Therapeutic treatments for repetitive hand washing |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US20040226556A1 (en) * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| US7270287B2 (en) * | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
| US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
| US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
| US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
| US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
| US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
| US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
| DE602005011458D1 (de) * | 2004-09-01 | 2009-01-15 | Allergan Inc | Abbaubare clostridientoxine |
| US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
| US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
| US7785606B2 (en) * | 2004-11-22 | 2010-08-31 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| WO2006059093A2 (en) * | 2004-12-01 | 2006-06-08 | Health Protection Agency | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| PL1877073T3 (pl) * | 2004-12-01 | 2014-03-31 | The Sec Dep For Health | Niecytotoksyczne koniugaty białkowe |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
| US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
| US7749515B2 (en) * | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
| RU2007136616A (ru) * | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
| JP2008532549A (ja) * | 2005-03-15 | 2008-08-21 | アラーガン、インコーポレイテッド | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US7731411B2 (en) * | 2005-04-04 | 2010-06-08 | Schlumberger Technology Corporation | Circulating fluid system for powder fluidization and method of performing same |
| ES2259928B1 (es) * | 2005-04-08 | 2007-11-01 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales. |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
| EP1926744B2 (en) * | 2005-09-19 | 2018-10-24 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
| US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
| US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
| WO2007106115A1 (en) | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
| US7811586B2 (en) * | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
| CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| CA2657460A1 (en) | 2006-07-11 | 2008-09-04 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| EP2038298A2 (en) * | 2006-07-11 | 2009-03-25 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP2010500967A (ja) * | 2006-07-20 | 2010-01-14 | ザ ジェネラル ホスピタル コーポレイション | コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット |
| US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
| US20080092910A1 (en) * | 2006-10-18 | 2008-04-24 | Allergan, Inc. | Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures |
| US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
| JP2010514779A (ja) * | 2006-12-29 | 2010-05-06 | ルバンス セラピュティックス インク． | 逆配列ｈｉｖ−ｔａｔポリペプチドを用いる輸送分子 |
| KR20170016031A (ko) * | 2007-07-26 | 2017-02-10 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
| MX2010004488A (es) * | 2007-10-23 | 2010-06-17 | Allergan Inc | Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas. |
| RU2010120016A (ru) * | 2007-10-23 | 2011-11-27 | Аллерган, Инк. (Us) | Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов |
| US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
| ES2398052T5 (es) | 2008-05-09 | 2021-10-25 | Nuvaira Inc | Sistemas para tratar un árbol bronquial |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| KR101731655B1 (ko) | 2008-06-12 | 2017-05-11 | 입센 바이오이노베이션 리미티드 | 암 억제 방법 |
| EP3590956A1 (en) * | 2008-06-12 | 2020-01-08 | Ipsen Bioinnovation Limited | Suppression of neuroendocrine diseases |
| JP5746624B2 (ja) * | 2008-08-29 | 2015-07-08 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | 変化した持続性を有するクロストリジウム性神経毒 |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
| US8259461B2 (en) * | 2008-11-25 | 2012-09-04 | Micron Technology, Inc. | Apparatus for bypassing faulty connections |
| CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| JP2012512162A (ja) | 2008-12-10 | 2012-05-31 | アラーガン、インコーポレイテッド | クロストリジウム毒素医薬組成物 |
| SG10202100698QA (en) | 2008-12-31 | 2021-02-25 | Revance Therapeutics Inc | Injectable Botulinum Toxin Formulations |
| RU2543650C2 (ru) * | 2009-03-13 | 2015-03-10 | Аллерган, Инк. | Иммунологические тесты на активность эндопептидаз с измененной нацеленностью |
| CN102869373B (zh) | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| CA2770185C (en) | 2009-08-17 | 2019-04-09 | East Carolina University | Fast acting snare-cleaving enzymes |
| WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
| EP2482838A4 (en) | 2009-09-30 | 2013-04-10 | Toxcure Inc | USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE |
| EP2926757B1 (en) | 2009-10-27 | 2023-01-25 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
| US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
| CN106618731B (zh) | 2009-11-11 | 2020-08-07 | 努瓦拉公司 | 用于处理组织和控制狭窄的系统、装置和方法 |
| RU2012129557A (ru) | 2009-12-16 | 2014-01-27 | Аллерган, Инк. | МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ |
| PT2528940E (pt) | 2010-01-25 | 2014-06-24 | Allergan Inc | Métodos de conversão intracelular de proteínas de cadeia única na sua forma de cadeia dupla |
| NZ703378A (en) | 2010-05-20 | 2016-10-28 | Allergan Inc | Degradable clostridial toxins |
| JP5779848B2 (ja) * | 2010-07-30 | 2015-09-16 | セイコーエプソン株式会社 | 液体吐出装置、液体吐出装置の駆動方法以上 |
| WO2012048246A1 (en) | 2010-10-08 | 2012-04-12 | Allergan, Inc. | Reduction of antibody response against botulinum neurotoxin and variants thereof |
| EP2646107A2 (en) * | 2010-12-01 | 2013-10-09 | Spinal Modulation Inc. | Agent delivery systems for selective neuromodulation |
| AU2011354196B2 (en) * | 2011-01-04 | 2015-12-17 | Sanofi-Aventis Deutschland Gmbh | Adaptor means for use in combination with a pre-filled syringe and a safety device, safety device and injection device |
| WO2012103415A1 (en) | 2011-01-28 | 2012-08-02 | Allergan, Inc. | Dosage regimen for the treatment of multiple disorders with botulinum toxins |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| KR20140054028A (ko) | 2011-07-08 | 2014-05-08 | 알러간, 인코포레이티드 | 자율신경계 장애의 치료방법 |
| US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
| BR112014001066A2 (pt) | 2011-07-20 | 2017-02-21 | Allergan Inc | toxinas botulínicas para uso em um método para tratamento de depósitos adiposos |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| CN104736166B (zh) | 2012-05-30 | 2018-02-16 | 哈佛大学校长及研究员协会 | 工程化的肉毒神经毒素 |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| GB201219024D0 (en) | 2012-10-23 | 2012-12-05 | Syntaxin Ltd | Assay |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| JP2016513082A (ja) | 2013-01-28 | 2016-05-12 | ニューヨーク・ユニバーシティ | 無毒性神経毒誘導体を用いる治療方法 |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| AU2015220915B2 (en) * | 2014-02-19 | 2020-09-17 | Merz Pharma Gmbh & Co. Kgaa | Gangliosides for standardizing and increasing the sensitivity of cells to Botulinum neurotoxins in in vitro test systems |
| EP3567055A1 (en) | 2014-07-07 | 2019-11-13 | Allergan, Inc. | Method of detecting cleaved snap25 in tissue samples |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| JP7017932B2 (ja) | 2014-12-09 | 2022-02-09 | ニューヨーク・ユニバーシティ | クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法 |
| PT3242884T (pt) | 2015-01-09 | 2021-04-22 | Ipsen Bioinnovation Ltd | Neurotoxinas catiónicas |
| RU2746736C2 (ru) | 2015-03-26 | 2021-04-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Сконструированный ботулинический нейротоксин |
| EP3341391A4 (en) | 2015-08-27 | 2019-03-06 | President and Fellows of Harvard College | COMPOSITIONS AND METHODS OF PAIN TREATMENT |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| AU2017277905B2 (en) | 2016-06-08 | 2022-04-14 | Children's Medical Center Corporation | Engineered Botulinum neurotoxins |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| FI3481852T3 (fi) | 2016-07-08 | 2023-03-19 | Childrens Medical Center | Uusi botulinum-neurotoksiini ja sen johdannaisia |
| EP3504226A1 (en) * | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| CA3035473A1 (en) | 2016-09-13 | 2018-03-22 | Allergan, Inc. | Non-protein clostridial toxin compositions |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| CN109790204A (zh) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | 杂合神经毒素 |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| HUE064332T2 (hu) | 2016-10-20 | 2024-03-28 | Harvard College | In vitro és sejtalapú esszék botulinum neurotoxinok aktivitásának mérésére |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2019067815A2 (en) | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
| EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
| WO2019145577A1 (en) | 2018-01-29 | 2019-08-01 | Ipsen Biopharm Limited | Non-neuronal snare-cleaving botulinum neurotoxins |
| CN111465352B (zh) | 2018-02-26 | 2024-04-12 | 益普生生物制药有限公司 | 使用超声波引导非细胞毒性蛋白酶的注射 |
| CN112165955A (zh) | 2018-05-21 | 2021-01-01 | 益普生生物制药有限公司 | 抑制骨癌引起的异常性疼痛 |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| LT3660509T (lt) | 2018-11-29 | 2022-05-10 | Hugel Inc. | Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti |
| US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| KR20230163470A (ko) | 2021-03-30 | 2023-11-30 | 입센 바이오팜 리미티드 | 통증 ＆ 염증성 장애의 치료 |
| CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| AU657087B2 (en) | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
| WO1992015327A1 (en) | 1991-03-08 | 1992-09-17 | Protein Design Labs, Inc. | Recombinant double chain immunotoxins |
| JPH06509563A (ja) * | 1991-07-05 | 1994-10-27 | セラゲン・インコーポレイテッド | 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子 |
| WO1993004191A1 (en) | 1991-08-15 | 1993-03-04 | Neorx Corporation | Noncytolytic toxin conjugates |
| DE4139001A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| CA2153781A1 (en) * | 1993-01-15 | 1994-07-21 | Gary E. Borodic | Method for treating myofascial pain syndrome |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| WO1994028923A1 (en) * | 1993-06-10 | 1994-12-22 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
| HUT78048A (hu) | 1994-10-24 | 1999-07-28 | Ophidian Pharmaceuticals, Inc. | A C. difficile által okozott betegség kezelésére és megelőzésére szolgáló vakcina és antitoxin |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5898545A (en) * | 1997-07-01 | 1999-04-27 | International Business Machines Corporation | Head load/unload and disk airflow control apparatus |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
-
1995
- 1995-04-21 GB GBGB9508204.6A patent/GB9508204D0/en active Pending
-
1996
- 1996-03-18 SG SG1996006595A patent/SG52602A1/en unknown
- 1996-04-16 TR TR97/01215T patent/TR199701215T1/xx unknown
- 1996-04-16 JP JP53154696A patent/JP4304241B2/ja not_active Expired - Fee Related
- 1996-04-16 BR BR9609870A patent/BR9609870A/pt not_active Application Discontinuation
- 1996-04-16 WO PCT/GB1996/000916 patent/WO1996033273A1/en active IP Right Grant
- 1996-04-16 US US08/945,037 patent/US5989545A/en not_active Expired - Lifetime
- 1996-04-16 SK SK1435-97A patent/SK143597A3/sk unknown
- 1996-04-16 NZ NZ305411A patent/NZ305411A/xx unknown
- 1996-04-16 CN CN96194505A patent/CN1122718C/zh not_active Expired - Fee Related
- 1996-04-16 PT PT96910091T patent/PT826051E/pt unknown
- 1996-04-16 CZ CZ973322A patent/CZ332297A3/cs unknown
- 1996-04-16 PL PL96323006A patent/PL323006A1/xx unknown
- 1996-04-16 AT AT96910091T patent/ATE274581T1/de active
- 1996-04-16 AU AU53398/96A patent/AU705924B2/en not_active Ceased
- 1996-04-16 DE DE69633228T patent/DE69633228T2/de not_active Expired - Lifetime
- 1996-04-16 KR KR1019970707466A patent/KR19990007943A/ko not_active Application Discontinuation
- 1996-04-16 RU RU97119181/13A patent/RU2165976C2/ru active
- 1996-04-16 ES ES96910091T patent/ES2225876T3/es not_active Expired - Lifetime
- 1996-04-16 CA CA2218857A patent/CA2218857C/en not_active Expired - Fee Related
- 1996-04-16 HU HU9802392A patent/HUP9802392A3/hu unknown
- 1996-04-16 EP EP96910091A patent/EP0826051B1/en not_active Expired - Lifetime
- 1996-04-19 ZA ZA963129A patent/ZA963129B/xx unknown
-
1997
- 1997-10-20 NO NO974845A patent/NO974845L/no not_active Application Discontinuation
- 1997-10-21 BG BG101984A patent/BG101984A/xx unknown
-
1999
- 1999-11-22 US US09/447,356 patent/US6395513B1/en not_active Expired - Lifetime
-
2002
- 2002-05-20 US US10/150,262 patent/US6962703B2/en not_active Expired - Fee Related
-
2005
- 2005-09-26 US US11/234,250 patent/US8158132B2/en not_active Expired - Fee Related
-
2007
- 2007-06-28 US US11/819,650 patent/US7887810B2/en not_active Expired - Fee Related
- 2007-06-28 US US11/819,648 patent/US7892560B2/en not_active Expired - Fee Related
-
2011
- 2011-10-11 US US13/270,662 patent/US20120141511A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK143597A3 (en) | Clostridial toxin derivatives able to modify peripheral sensory afferent functions | |
| US7456272B2 (en) | Neurotoxins with enhanced target specificity | |
| US9234011B2 (en) | Transport protein which is used to introduce chemical compounds into nerve cells | |
| US7833535B2 (en) | Clostridial toxin derivatives and methods for treating pain | |
| KR20040105818A (ko) | 심혈관 질환의 처치에 사용되는 보툴리눔 독소 | |
| Simpson | Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs | |
| JPH09507234A (ja) | 種々の疾病およびそれに伴う疼痛を処置するためのボツリヌス毒素 | |
| US10022450B2 (en) | Regulation of specific spinal neurons regulating pain transmission via chimeric toxins | |
| MXPA97008124A (en) | Botulinum toxin derivatives capable of modifying perfery affording functions |